Joshua F. Zeidner, MD, presents data from the 62nd American Society of Hematology (ASH) Annual Meeting on an exploratory analysis of patient-reported outcomes from a randomized phase 2 trial of pevonedistat plus azacitidine vs azacitidine in higher-risk myelodysplastic syndrome (MDS)/chronic myelomonocytic leukemia (CMML) or low-blast acute myeloid leukemia (AML).
Joshua F. Zeidner, MD, discusses data from the following presentation:
1. Ades L et al. ASCO 2020 annual meeting. Abstract 7506.
2. Coens C et al. Lancet Oncol. 2020;21(2):e83-e96.